Real world results from a post-approval safety surveillance of tofacitinib (Xeljanz): Over 3 year results from an ongoing US-based rheumatoid arthritis registry - Kavanaugh, A F; Geier, J; Bingham, C (Arthritis Rheumatol, 2016)
et al.